Cargando…

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

Personalized healthcare relies on accurate companion diagnostic assays that enable the most appropriate treatment decision for cancer patients. Extensive assay validation prior to use in a clinical setting is essential for providing a reliable test result. This poses a challenge for low prevalence m...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bruin, Elza C., Whiteley, Jessica L., Corcoran, Claire, Kirk, Pauline M., Fox, Jayne C., Armisen, Javier, Lindemann, Justin P. O., Schiavon, Gaia, Ambrose, Helen J., Kohlmann, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417426/ https://www.ncbi.nlm.nih.gov/pubmed/28472036 http://dx.doi.org/10.1371/journal.pone.0175779

Ejemplares similares

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015)

E17K substitution in AKT1 in prostate cancer
por: Boormans, J L, et al.
Publicado: (2010)

Mer1p is a modular splicing factor whose function depends on the conserved U2 snRNP protein Snu17p
por: Spingola, Marc, et al.
Publicado: (2006)

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting
por: Do, Hongdo, et al.
Publicado: (2008)

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Sherwood, James L., et al.
Publicado: (2016)

Human uterine and placental arteries exhibit tissue-specific acute responses to 17β-estradiol and estrogen-receptor-specific agonists
por: Corcoran, Jemma J., et al.
Publicado: (2014)

Mutant AKT1-E17K is oncogenic in lung epithelial cells
por: De Marco, Carmela, et al.
Publicado: (2015)

The AKT1E17K Allele Promotes Breast Cancer in Mice
por: Malanga, Donatella, et al.
Publicado: (2022)

Targeting AKT-Dependent Regulation of Antioxidant Defense Sensitizes AKT-E17K Expressing Cancer Cells to Ionizing Radiation
por: Goetting, Isabell, et al.
Publicado: (2022)

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
por: Turner, N C, et al.
Publicado: (2019)

Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
por: Mancini, Maria L., et al.
Publicado: (2016)

Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
por: Chen, Ying, et al.
Publicado: (2020)

Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations
por: Kingston, Belinda, et al.
Publicado: (2019)

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
por: Howell, Sacha J, et al.
Publicado: (2022)

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
por: Kim, M S, et al.
Publicado: (2008)

Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver
por: Riener, M-O, et al.
Publicado: (2008)

Prediction of a highly deleterious mutation E17K in AKT-1 gene: An in silico approach
por: Khan, Imran, et al.
Publicado: (2017)

The importance of accurate developmental staging
por: Ober, Eric S, et al.
Publicado: (2020)

Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications
por: de Bruin, Elza C, et al.
Publicado: (2013)

Analysis of intratumor heterogeneity unravels lung cancer evolution
por: de Bruin, Elza C, et al.
Publicado: (2015)

Selectors
por: Jayne, John E, et al.
Publicado: (2001)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

A quantitative framework reveals traditional laboratory growth is a highly accurate model of human oral infection
por: Lewin, Gina R., et al.
Publicado: (2022)

AKT1(E17K) Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
por: Malanga, Donatella, et al.
Publicado: (2016)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Human Peritoneal Mesothelial Cell Death Induced by High-Glucose Hypertonic Solution Involves Ca(2+) and Na(+) Ions and Oxidative Stress with the Participation of PKC/NOX2 and PI3K/Akt Pathways
por: Simon, Felipe, et al.
Publicado: (2017)

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
por: Hiley, Crispin, et al.
Publicado: (2014)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias
por: Mahmoud, I S, et al.
Publicado: (2008)

Ginkgol C17:1 inhibits tumor growth by blunting the EGF- PI3K/Akt signaling pathway
por: Li, Yueying, et al.
Publicado: (2017)

A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours
por: Adams, Claire L., et al.
Publicado: (2020)

The PI3K/Akt Pathway in Tumors of Endocrine Tissues
por: Robbins, Helen Louise, et al.
Publicado: (2016)

Highly Accurate Diagnosis of Pleural Tuberculosis by Immunological Analysis of the Pleural Effusion
por: Sutherland, Jayne S., et al.
Publicado: (2012)

Common DNA Variants Accurately Rank an Individual of Extreme Height
por: Sexton, Corinne E., et al.
Publicado: (2018)

RapGene: a fast and accurate strategy for synthetic gene assembly in Escherichia coli
por: Zampini, Massimiliano, et al.
Publicado: (2015)

Towards accurate modeling of noncovalent interactions for protein rigidity analysis
por: Fox, Naomi, et al.
Publicado: (2013)

Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain
por: Kumar, Ambuj, et al.
Publicado: (2013)

AKT1(E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
por: Rudolph, Marion, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fiar61hr989u4aniumciavfuha